MedTrace Logo

A Study of KL130008 in Adults With Severe Alopecia Areata

NCT05496426 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2026-05-12

No results posted yet for this study

Summary

The purpose of this study is to assess KL130008 is safe and effective in adults with severe alopecia areata

Conditions

Interventions

DRUG

KL130008/Placebo

Drug: KL130008 Drug: Placebo

Sponsors & Collaborators

  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xingqi Zhang · First Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-09
Primary Completion
2024-04-16
Completion
2024-04-16

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05496426 on ClinicalTrials.gov